Long Term Outcome After Serial Lidocaine Infusion in Peripheral Neuropathic Pain

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

29 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-08-01

Study Completion Date

2018-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study to evaluated Long term outcome after serial Lidocaine infusion when compared with placebo in peripheral neuropathic pain patients in acute stage (less than 6 months) at 3 months after first time of infusion

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Tolerability of Lidocaine Plaster for Treatment of Long-term Local Nerve Pain

NCT01752322

Pain Chronic Pain Neuropathic Pain +1 more

COMPLETED PHASE3

The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin

NCT01669967

Neuropathic Pain

COMPLETED NA

IV Lidocaine Infusion for Neuropathic Pain

NCT05731739

Neuropathic Pain Complex Regional Pain Syndrome Chronic Pain

WITHDRAWN

Efficacy and Safety of Lidocaine Infusion Treatment in Management of Neuropathic Pain

NCT02597257

Postherpetic Neuralgia Diabetic Polyneuropathy Peripheral Neuropathy

UNKNOWN PHASE2

Clinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30 Subjects With an Ongoing History of Significant PLP.--FDA and IRB Approved.

NCT07276542

Phantom Limb Syndrome With Pain

NOT_YET_RECRUITING PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Peripheral nerve injury may give rise to severe and long-lasting types of pains which are often resistant to treatment such as opioid, tricyclic antidepressant or anticonvulsant. Lidocaine infusion has been the one of intractable neuropathic pain treatment . My hypothesis the serial lidocaine infusion can adequate pain control and can prevent chronic pain (central sensitisation). Therefore, we designed this prospective, randomised, double-blind, controlled study to evaluate the efficacy of serial lidocaine infusion in peripheral neuropathic pain compared with placebo in long term outcome (at 3 month).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo group

Normal Saline 50 ml intravenous infusion in 1 hour once a week 4 times

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Lidocaine group

Lidocaine 3mg/kg in Normal Saline to 50 ml intravenous infusion in 1 hour once a week 4 times

Group Type ACTIVE_COMPARATOR

Lidocaine

Intervention Type DRUG

Lidocaine 3 mg/kg dilute in Normal Saline to 50 ml intravenous infusion in 1 hour

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lidocaine

Lidocaine 3 mg/kg dilute in Normal Saline to 50 ml intravenous infusion in 1 hour

Intervention Type DRUG

Placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Intravenous lidocaine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Peripheral neuropathic pain from peripheral nerve injury within 6 months after injury
* Well understand to Thai language in writing or listening

Exclusion Criteria

* Underlying Heart disease or Arrhythmia
* Allergy to lidocaine, Gabapentin, Carbamazepine, tramadol
* History of epilepsy
* History of lidocaine used
* Underlying Psychiatric disease
* History of drug abuse
* Pregnancy and nursing

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes